tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Prurigo D011536 4 associated lipids
Meningoencephalitis D008590 4 associated lipids
Herpesviridae Infections D006566 4 associated lipids
Gastroenteritis D005759 4 associated lipids
Viremia D014766 4 associated lipids
Hepatitis, Viral, Animal D006524 4 associated lipids
Fractures, Spontaneous D005598 4 associated lipids
Gout D006073 4 associated lipids
Pemphigoid, Benign Mucous Membrane D010390 4 associated lipids
Ovarian Cysts D010048 4 associated lipids
Myasthenia Gravis D009157 5 associated lipids
Uveitis, Posterior D015866 5 associated lipids
Osteomalacia D010018 5 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Trypanosomiasis D014352 5 associated lipids
Liver Failure D017093 5 associated lipids
Osteonecrosis D010020 5 associated lipids
Anemia, Hemolytic, Autoimmune D000744 5 associated lipids
Enterobacteriaceae Infections D004756 5 associated lipids
Femur Head Necrosis D005271 5 associated lipids
Hematoma D006406 5 associated lipids
Vasculitis, Leukocytoclastic, Cutaneous D018366 5 associated lipids
Erythema Nodosum D004893 5 associated lipids
Respiration Disorders D012120 5 associated lipids
Skin Diseases, Vesiculobullous D012872 5 associated lipids
Hand Dermatoses D006229 5 associated lipids
Postoperative Complications D011183 5 associated lipids
Lung Diseases, Interstitial D017563 5 associated lipids
Sclerosis D012598 5 associated lipids
Mastocytosis D008415 5 associated lipids
Mouth Diseases D009059 5 associated lipids
Intestinal Pseudo-Obstruction D007418 5 associated lipids
Tinea D014005 5 associated lipids
Pericarditis D010493 6 associated lipids
Blindness D001766 6 associated lipids
Alopecia Areata D000506 6 associated lipids
Nocardia Infections D009617 6 associated lipids
Gliosis D005911 6 associated lipids
Bronchiolitis D001988 6 associated lipids
Infection D007239 6 associated lipids
Pancytopenia D010198 6 associated lipids
Ataxia Telangiectasia D001260 6 associated lipids
Sarcoma, Kaposi D012514 6 associated lipids
Graves Disease D006111 6 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Purpura, Thrombotic Thrombocytopenic D011697 6 associated lipids
Glomerulonephritis, Membranous D015433 6 associated lipids
Angioedema D000799 6 associated lipids
Thrombophlebitis D013924 6 associated lipids
Gynecomastia D006177 6 associated lipids
Anemia, Iron-Deficiency D018798 6 associated lipids
Heart Injuries D006335 6 associated lipids
Cardiomyopathy, Hypertrophic D002312 6 associated lipids
Coronary Stenosis D023921 6 associated lipids
Liver Abscess D008100 6 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Folliculitis D005499 7 associated lipids
Granuloma, Giant Cell D006101 7 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Food Hypersensitivity D005512 7 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Chronic Disease D002908 7 associated lipids
Metaplasia D008679 7 associated lipids
Dyslipidemias D050171 7 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Behcet Syndrome D001528 7 associated lipids
Hepatitis C D006526 7 associated lipids
Biliary Tract Neoplasms D001661 7 associated lipids
Lymphoproliferative Disorders D008232 7 associated lipids
Dementia, Vascular D015140 7 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Sleep Wake Disorders D012893 7 associated lipids
Facial Dermatoses D005148 7 associated lipids
Postoperative Hemorrhage D019106 7 associated lipids
Tachycardia D013610 7 associated lipids
Opportunistic Infections D009894 8 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Candidiasis, Vulvovaginal D002181 8 associated lipids
Immunologic Deficiency Syndromes D007153 8 associated lipids
Arthritis, Juvenile D001171 8 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Pemphigoid, Bullous D010391 8 associated lipids
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Lupus Nephritis D008181 8 associated lipids
Thyroid Diseases D013959 8 associated lipids
Fistula D005402 8 associated lipids
Renal Insufficiency D051437 8 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Periodontal Pocket D010514 9 associated lipids
Urination Disorders D014555 9 associated lipids
Inflammatory Bowel Diseases D015212 9 associated lipids
Hypertension, Renal D006977 9 associated lipids
Tachycardia, Ventricular D017180 9 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Sinusitis D012852 9 associated lipids
Thyroiditis, Autoimmune D013967 9 associated lipids
Leukocytosis D007964 9 associated lipids
Cicatrix D002921 9 associated lipids
Precursor Cell Lymphoblastic Leukemia-Lymphoma D054198 10 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Alak AM et al. An HPLC/MS/MS assay for tacrolimus in patient blood samples. Correlation with results of an ELISA assay. 1997 J Pharm Biomed Anal pmid:9447546
Butcher SP et al. Neuroprotective actions of FK506 in experimental stroke: in vivo evidence against an antiexcitotoxic mechanism. 1997 J. Neurosci. pmid:9278529
Singh N et al. Predictors and outcome of early- versus late-onset major bacterial infections in liver transplant recipients receiving tacrolimus (FK506) as primary immunosuppression. 1997 Eur. J. Clin. Microbiol. Infect. Dis. pmid:9447904
Hohage H et al. Effects of cyclosporin A and FK 506 on lipid metabolism and fibrinogen in kidney transplant recipients. 1997 Clin Transplant pmid:9193847
Gold BG et al. A nonimmunosuppressant FKBP-12 ligand increases nerve regeneration. 1997 Exp. Neurol. pmid:9344552
Katari SR et al. Clinical features of acute reversible tacrolimus (FK 506) nephrotoxicity in kidney transplant recipients. 1997 Clin Transplant pmid:9193849
Ciancio G et al. Post-transplant lymphoproliferative disease in kidney transplant patients in the new immunosuppressive era. 1997 Clin Transplant pmid:9193850
Jindal RM Post-transplant hyperlipidaemia. 1997 Postgrad Med J pmid:9497947
Koneru B et al. Blood transfusions in liver recipients: a conundrum or a clear benefit in the cyclosporine/tacrolimus era? 1997 Transplantation pmid:9197350
Cameron AM et al. FKBP12 binds the inositol 1,4,5-trisphosphate receptor at leucine-proline (1400-1401) and anchors calcineurin to this FK506-like domain. 1997 J. Biol. Chem. pmid:9346894
Sugitani A et al. En bloc pancreas and kidney transplantation in a patient with limited vascular access. 1997 Transplantation pmid:9197366
Hosoi R et al. Isoform-specific up-regulation by ouabain of Na+,K+-ATPase in cultured rat astrocytes. 1997 J. Neurochem. pmid:9349566
Guerini D Calcineurin: not just a simple protein phosphatase. 1997 Biochem. Biophys. Res. Commun. pmid:9199180
Krüger M et al. Inhibition of CREB- and cAMP response element-mediated gene transcription by the immunosuppressive drugs cyclosporin A and FK506 in T cells. 1997 Naunyn Schmiedebergs Arch. Pharmacol. pmid:9349628
Rouviere N et al. Immunosuppressor binding to the immunophilin FKBP59 affects the local structural dynamics of a surface beta-strand: time-resolved fluorescence study. 1997 Biochemistry pmid:9200682
Prokisch H et al. Impairment of calcineurin function in Neurospora crassa reveals its essential role in hyphal growth, morphology and maintenance of the apical Ca2+ gradient. 1997 Mol. Gen. Genet. pmid:9349701
Alak AM Measurement of tacrolimus (FK506) and its metabolites: a review of assay development and application in therapeutic drug monitoring and pharmacokinetic studies. 1997 Ther Drug Monit pmid:9200777
Saitoh O et al. Cyclosporine A inhibits interleukin-8 production in a human colon epithelial cell line (HT-29). 1997 J. Gastroenterol. pmid:9349985
Kageyama M et al. FK506-binding proteins regulate smooth muscle contractility by altering neurotransmitter release. 1997 Eur. J. Pharmacol. pmid:9314039
de Paulis A et al. Human synovial mast cells. II. Heterogeneity of the pharmacologic effects of antiinflammatory and immunosuppressive drugs. 1997 Arthritis Rheum. pmid:9082935
Yasutomi M et al. Evaluation of tetrahydropyranyladriamycin as an immunosuppressant in concordant xenotransplantation. 1997 J. Heart Lung Transplant. pmid:9087871
Kitagaki K et al. Facilitation of apoptosis by cyclosporins A and H, but not FK506 in mouse bronchial eosinophils. 1997 Eur. J. Pharmacol. pmid:9430427
Morrissey PE et al. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria. 1997 Transplantation pmid:9089224
Midtvedt K et al. Successful pregnancies in a combined pancreas and renal allograft recipient and in a renal graft recipient on tacrolimus treatment. 1997 Nephrol. Dial. Transplant. pmid:9430893
Kiuchi T et al. A hepatic graft tuberculosis transmitted from a living-related donor. 1997 Transplantation pmid:9089234
Paterson DL and Singh N Interactions between tacrolimus and antimicrobial agents. 1997 Clin. Infect. Dis. pmid:9431391
Krämer BK and Schweda F Differing proteinuria control with cyclosporin and tacrolimus. 1997 Lancet pmid:9093272
Openshaw H Peripheral neuropathy after bone marrow transplantation. 1997 Biol. Blood Marrow Transplant. pmid:9360782
Maurer M et al. Hair growth modulation by topical immunophilin ligands: induction of anagen, inhibition of massive catagen development, and relative protection from chemotherapy-induced alopecia. 1997 Am. J. Pathol. pmid:9094998
Rinaldi M et al. FK506 effectiveness in reducing acute rejection after heart transplantation: a prospective randomized study. 1997 J. Heart Lung Transplant. pmid:9361242
Steiner JP et al. Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A. 1997 Nat. Med. pmid:9095176
Nakai A et al. The immunosuppressant drug FK506 ameliorates secondary mitochondrial dysfunction following transient focal cerebral ischemia in the rat. 1997 Neurobiol. Dis. pmid:9361306
Reyes J et al. Graft-versus-host disease after liver and small bowel transplantation in a child. 1997 Clin Transplant pmid:9361921
Blau CA et al. A proliferation switch for genetically modified cells. 1997 Proc. Natl. Acad. Sci. U.S.A. pmid:9096348
Neu AM et al. Evaluation of neurotoxicity in pediatric renal transplant recipients treated with tacrolimus (FK506). 1997 Clin Transplant pmid:9361932
Garcia-Morales R et al. The effects of chimeric cells following donor bone marrow infusions as detected by PCR-flow assays in kidney transplant recipients. 1997 J. Clin. Invest. pmid:9062371
Xenos EX et al. The use of tacrolimus as induction and maintenance immunosuppression in renal cadaveric transplant recipients over the age of 60. 1997 Clin Transplant pmid:9361949
Göthel SF et al. An internal FK506-binding domain is the catalytic core of the prolyl isomerase activity associated with the Bacillus subtilis trigger factor. 1997 Eur. J. Biochem. pmid:9063446
Karlsson H and Nässberger L FK506 suppresses the mitogen-induced increase in lymphocyte adhesiveness to endothelial cells, but does not affect endothelial cell activation in response to inflammatory stimuli. 1997 Transplantation pmid:9355847
Ishida H et al. Cataract development induced by repeated oral dosing with FK506 (tacrolimus) in adult rats. 1997 Toxicology pmid:9355935
Wang JH and Kelly PT Attenuation of paired-pulse facilitation associated with synaptic potentiation mediated by postsynaptic mechanisms. 1997 J. Neurophysiol. pmid:9356420
Lee JW et al. Tacrolimus (FK506): validation of a sensitive enzyme-linked immunosorbent assay kit for and application to a clinical pharmacokinetic study. 1997 Ther Drug Monit pmid:9108651
Thyagarajan GK et al. FK506-induced fulminant leukoencephalopathy after single-lung transplantation. 1997 Ann. Thorac. Surg. pmid:9386723
Holt DW and Johnston A Tacrolimus quality assessment. 1997 Ther Drug Monit pmid:9108659
Wang MS et al. Comparative dose-dependence study of FK506 and cyclosporin A on the rate of axonal regeneration in the rat sciatic nerve. 1997 J. Pharmacol. Exp. Ther. pmid:9262378
McElwee KJ et al. Topical FK506: a potent immunotherapy for alopecia areata? Studies using the Dundee experimental bald rat model. 1997 Br. J. Dermatol. pmid:9390322
Pirsch JD et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. 1997 Transplantation pmid:9112351
Zhang Q et al. A specific method for the measurement of tacrolimus in human whole blood by liquid chromatography/tandem mass spectrometry. 1997 Ther Drug Monit pmid:9263391
Huang J and Schreiber SL A yeast genetic system for selecting small molecule inhibitors of protein-protein interactions in nanodroplets. 1997 Proc. Natl. Acad. Sci. U.S.A. pmid:9391035
Hikita N et al. Use of topical FK506 in a corneal graft rejection model in Lewis rats. 1997 Invest. Ophthalmol. Vis. Sci. pmid:9112986
Hickman PE et al. Clinical chemistry and post-liver-transplant monitoring. 1997 Clin. Chem. pmid:9265907
Nyanguile O et al. A nonnatural transcriptional coactivator. 1997 Proc. Natl. Acad. Sci. U.S.A. pmid:9391036
Aicher L et al. Decrease in kidney calbindin-D 28kDa as a possible mechanism mediating cyclosporine A- and FK-506-induced calciuria and tubular mineralization. 1997 Biochem. Pharmacol. pmid:9113092
Paterson DL et al. Could a herpesvirus mimic tacrolimus-induced leukoencephalopathy? 1997 Ann. Neurol. pmid:9266742
Kageyama S et al. Augmentation of natural killer cell activity induced by cytomegalovirus infection in mice treated with FK506. 1997 Acta Virol. pmid:9391652
Ahsan N et al. Successful reversal of acute vascular rejection in a renal allograft with combined mycophenolate mofetil and tacrolimus as primary immunotherapy. 1997 Clin Transplant pmid:9113443
Yoshimoto T et al. [Leukoencephalopathy probably caused by tacrolimus hydrate after stem cell transplantation in a girl with MDS 7 monosomy]. 1997 Rinsho Ketsueki pmid:9267167
Sokal EM et al. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. 1997 Transplantation pmid:9392308
Singh N et al. Invasive fungal infections in liver transplant recipients receiving tacrolimus as the primary immunosuppressive agent. 1997 Clin. Infect. Dis. pmid:9114144
Alessiani M et al. [Flexibility of the surgical model of intestinal transplantation in swine]. 1997 Minerva Chir pmid:9432575
Ito E and Tanaka Y Influences of immunosuppressive agents, FK506 and cyclosporin on systemic Candida albicans infection in mice. 1997 Mycopathologia pmid:9433807
Boucek MM et al. The Registry of the International Society of Heart and Lung Transplantation: first official pediatric report--1997. 1997 J. Heart Lung Transplant. pmid:9436131
Hossain MA et al. Immunosuppression in auxiliary partial liver transplantation with FK506 in rats. 1997 Transplant. Proc. pmid:9414861
Weber M et al. Decreased rejection episodes in African-American renal transplant recipients receiving mycophenolate mofetil/tacrolimus therapy. 1997 Transplant. Proc. pmid:9414883
Scantlebury VP et al. Outcome of kidney transplantation in African-Americans using tacrolimus. 1997 Transplant. Proc. pmid:9414906
Gruessner RW et al. Solitary pancreas transplantation for nonuremic patients with labile insulin-dependent diabetes mellitus. 1997 Transplantation pmid:9415558
Lang T et al. Cholic acid synthesis is reduced in pediatric liver recipients during graft dysfunction due to ischemic injury and allograft rejection. 1997 Transplantation pmid:9415561
Marienfeld R et al. Cyclosporin A interferes with the inducible degradation of NF-kappa B inhibitors, but not with the processing of p105/NF-kappa B1 in T cells. 1997 Eur. J. Immunol. pmid:9247567
Massicot F et al. Modulation of energy status and cytotoxicity induced by FK506 and cyclosporin A in a renal epithelial cell line. 1997 Arch. Toxicol. pmid:9248632
Talbot D et al. Alopecia as a consequence of tacrolimus therapy in renal transplantation? 1997 Transplantation pmid:9415574
Newstead CG Tacrolimus in renal transplantation. 1997 Nephrol. Dial. Transplant. pmid:9249761
Neuhaus P et al. Tacrolimus-based immunosuppression after liver transplantation: a randomised study comparing dual versus triple low-dose oral regimens. 1997 Transpl. Int. pmid:9249934
Dhawan A et al. Tacrolimus (FK506) malabsorption: management with fluconazole coadministration. 1997 Transpl. Int. pmid:9249946
Nagai H et al. FK-506 and cyclosporin A potentiate the IgE antibody production by contact sensitization with hapten in mice. 1997 J. Pharmacol. Exp. Ther. pmid:9336339
Seifeldin RA et al. Nifedipine interaction with tacrolimus in liver transplant recipients. 1997 Ann Pharmacother pmid:9161650
Ballantyne CM et al. Pathophysiology and treatment of lipid perturbation after cardiac transplantation. 1997 Curr. Opin. Cardiol. pmid:9192484
Gruessner RW and Sharp HL Living-related intestinal transplantation: first report of a standardized surgical technique. 1997 Transplantation pmid:9415566
Holt DW and Johnston A Monitoring new immunosuppressive agents. Are the methods adequate? 1997 Drug Metabol Drug Interact pmid:9713574
Shapiro R et al. Reversibility of tacrolimus-induced posttransplant diabetes: an illustrative case and review of the literature. 1997 Transplant. Proc. pmid:9290809
Shaw LM Mycophenolate mofetil: pharmacokinetic strategies for optimizing immunosuppression. 1997 Drug Metabol Drug Interact pmid:9713576
Ilan Y et al. Transient immunosuppression with FK506 permits long-term expression of therapeutic genes introduced into the liver using recombinant adenoviruses in the rat. 1997 Hepatology pmid:9328318
Vella JP and Sayegh MH Maintenance pharmacological immunosuppressive strategies in renal transplantation. 1997 Postgrad Med J pmid:9338020
Gruessner AC and Sutherland DE Pancreas transplants for United States (US) and non-US cases as reported to the International Pancreas Transplant Registry (IPTR) and to the United Network for Organ Sharing (UNOS). 1997 Clin Transpl pmid:9919390
Ericzon BG et al. Secretion and composition of bile after human liver transplantation: studies on the effects of cyclosporine and tacrolimus. 1997 Transplantation pmid:9000664
Odorico JS et al. Advances in pancreas transplantation: the University of Wisconsin experience. 1997 Clin Transpl pmid:9919400
Kelly PA et al. Ciprofloxacin does not block the antiproliferative effect of tacrolimus. 1997 Transplantation pmid:9000686
Nair SC et al. Molecular cloning of human FKBP51 and comparisons of immunophilin interactions with Hsp90 and progesterone receptor. 1997 Mol. Cell. Biol. pmid:9001212
Pirenne J et al. Donor-specific unmodified bone marrow transfusion does not facilitate intestinal engraftment after bowel transplantation in a porcine model. 1997 Surgery pmid:9001555
Felldin M et al. Rescue therapy with tacrolimus (FK 506) in renal transplant recipients--a Scandinavian multicenter analysis. 1997 Transpl. Int. pmid:9002146
Steiner JP et al. Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. 1997 Proc. Natl. Acad. Sci. U.S.A. pmid:9050897
Seidel ER and Ragan VL Inhibition by rapamycin of ornithine decarboxylase and epithelial cell proliferation in intestinal IEC-6 cells in culture. 1997 Br. J. Pharmacol. pmid:9051292
Aoki Y and Kao PN Cyclosporin A-sensitive calcium signaling represses NFkappaB activation in human bronchial epithelial cells and enhances NFkappaB activation in Jurkat T-cells. 1997 Biochem. Biophys. Res. Commun. pmid:9177287
Prasad NV et al. Metabolism of tacrolimus (FK 506) in rat liver microsomes. Effect of rifampin and dexamethasone. 1997 Res. Commun. Mol. Pathol. Pharmacol. pmid:9178371
Alak AM and Moy S Biological activity of tacrolimus (FK506) and its metabolites from whole blood of kidney transplant patients. 1997 Transplant. Proc. pmid:9270821
Scholler G et al. Comparison of cyclosporine A and FK506 with regard to complaints and psychosocial characteristics before and after liver transplantation. 1997 Transplant. Proc. pmid:9270822
Pichlmayr R et al. Three-year follow-up of the European Multicenter Tacrolimus (FK506) Liver Study. 1997 Transplant. Proc. pmid:9270825
Rolfe FG et al. Cyclosporin A and FK506 reduce interleukin-5 mRNA abundance by inhibiting gene transcription. 1997 Am. J. Respir. Cell Mol. Biol. pmid:9271313
ten Berge RJ and Schellekens PT [Immunology in clinical practice. VI. Current immunosuppressive drugs]. 1997 Ned Tijdschr Geneeskd pmid:9550813
Mayer AD et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. 1997 Transplantation pmid:9275110
Guérette B et al. Prevention by anti-LFA-1 of acute myoblast death following transplantation. 1997 J. Immunol. pmid:9278346